Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study

Trial Profile

Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors SCRI Development Innovations
  • Most Recent Events

    • 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
    • 31 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top